Operations veteran of wine, CPG and tech industries to drive growth and operational excellence
MARKHAM, ON, June 22, 2017 /CNW/ - MedReleaf Corp. (TSX: LEAF), ("MedReleaf"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, announced today that Donald Courtney has been
"Wine, technology, food and CPG are all very relevant to the future of the global cannabis industry and we are very pleased to welcome Don to our leadership team given his impressive track record in these industries," said Neil Closner, CEO of MedReleaf. "Don brings the operational expertise necessary to support our continued growth while maintaining our industry-leading standards of product quality and production excellence."
Mr. Courtney brings to MedReleaf a wealth of relevant experience including senior operational roles at Vincor International, Canada's largest wine company at the time of its acquisition by Constellation Brands. Mr. Courtney has also held operations and management roles with both Pepsi Canada and Mars Incorporated as well as a number of technology companies including LG Electronics Canada where he served as COO.
"MedReleaf has built an industry lead in production and operational excellence and I am thrilled to be joining MedReleaf's world-class management team," said Don Courtney, COO of MedReleaf. "I look forward to leveraging my experience to help increase this lead as well as help prepare for the upcoming needs of the recreational market."
MedReleaf sets The Medical Grade Standard for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleafcanada.
Forward Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for MedReleaf to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in MedReleaf's Final Long Form Prospectus dated May 30, 2017 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in MedReleaf's Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.
SOURCE MedReleaf Corp.
Subscribe to our Free Newsletters!
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can ...
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...View All